Stockreport

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma [Yahoo! Finance]

Intensity Therapeutics, Inc.  (INTS) 
PDF SHELTON, Conn. July 9, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc . ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company foc [Read more]